# Nivolumab in Biochemically Recurrent dMMR Prostate Cancer

> **NCT04019964** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 8 (actual)

## Conditions studied

- Prostate Cancer
- Recurrent Prostate Cancer

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04019964
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-13
- **Primary completion:** 2025-04-23
- **Final completion:** 2025-07-03
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04019964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04019964, "Nivolumab in Biochemically Recurrent dMMR Prostate Cancer". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT04019964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*